Columbus, OHNCT05415709Now EnrollingIRB Ready

Fallopian Tube Endometrioid Adenocarcinoma Clinical Trial in Columbus, OH

Access cutting-edge fallopian tube endometrioid adenocarcinoma treatment through this clinical trial at a research site in Columbus. Study-provided care at no cost to qualified participants.

Sponsored by Ohio State University Comprehensive Cancer Center

Quick Self-Assessment

See if you qualify for this Columbus location

Preparing your pre-screening questions…

Expert Care in Columbus

Access fallopian tube endometrioid adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related fallopian tube endometrioid adenocarcinoma treatment provided free

Apply for This Columbus Location

Check if you qualify for this fallopian tube endometrioid adenocarcinoma clinical trial in Columbus, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Columbus

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Columbus site if eligible
  4. 4Begin participation

About This Fallopian Tube Endometrioid Adenocarcinoma Study in Columbus

This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial chemotherapy involves the infusion of heated cytotoxic chemotherapy that circulates into the abdominal cavity at the time of surgery. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery may kill more tumor cells compared to usual care.

Sponsor: Ohio State University Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Ability to understand (English-speaking), and willingness to sign a written, informed consent
Age \> 18 years old
Newly diagnosed stage III or IV epithelial (serous, mucinous, or endometrioid) ovarian, fallopian tube or peritoneal cancer diagnosed by:
Biopsy/histology (either by interventional radiology or laparoscopy) OR
Cytology; If diagnosis is based on cytology the following criteria must be met:
Immunohistochemistry on the block from cytology to demonstrate Mullerian origin
Presence of pelvic mass AND CA 125 \> 200kU/I AND CA125/CEA ratio \> 25 at initial diagnosis
Omental cake or other metastases larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size (diagnosed by computed tomography \[CT\]/magnetic resonance imaging \[MRI\], ultrasound, or laparoscopy)
Patient planned for or currently receiving neoadjuvant chemotherapy due to the fact that optimal primary CRS was determined not to be feasible by the primary surgeon
Patient must be planned or scheduled to undergo interval cytoreductive surgery after cycle 3-4 of neoadjuvant surgery
Completion of three cycles of neoadjuvant chemotherapy (NACT) with standard therapy (carboplatin \[area under the curve (AUC) 5-6\] day \[D\]1 + paclitaxel \[175 mg/m\^2\] D1 every 3 weeks)
Following 3-4 cycles of NACT partial or complete response
Following 3-4 cycles of NACT at least 50% decrease in CA-125 level between pre-cycle 1 and post-cycle 3/prior to surgery
Fit for major surgery, American Society of Anesthesiologists (ASA )1 or ASA 2
Eastern Cooperative Oncology Group (ECOG) performance-status score of 0-2
Serum creatinine \< 1.4 mg/dL
Creatinine clearance \> 60 ml/min (Cockcroft-Gault formula)
White blood cell count \> 3.5 x 10\^9 cells/L
Absolute neutrophil count \> 1.5 kg/ul
Platelets \> 100,000/ul
Total bilirubin within 1.5 x normal institutional limits
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x institutional upper limit of normal
For quality of life assessment, baseline questionnaires should be filled in before randomization

Exclusion Criteria

History of breast cancer or previous malignancy within 5 years prior to inclusion, with the exception of radically excised basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
Low grade serious carcinoma of the ovary or borderline ovarian tumors
History or current diagnosis of inflammatory bowel disease
History of allergic reactions to compounds of similar chemical or biologic composition to cisplatin, carboplatin, and paclitaxel
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
Patients in whom an optimal or complete cytoreduction cannot be performed will be excluded at the time of surgery and be replaced

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbus?

Yes, this clinical trial (NCT05415709) has an active research site in Columbus, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Fallopian Tube Endometrioid Adenocarcinoma Treatment Options in Columbus, OH

If you're searching for fallopian tube endometrioid adenocarcinoma treatment options in Columbus, OH, this clinical trial (NCT05415709) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbus research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fallopian tube endometrioid adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fallopian tube endometrioid adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Columbus, OH

See all leukemia clinical trials recruiting in Columbus — not just this study.

Browse Leukemia Trials in Columbus →

Browse More Trials by Condition

Leukemia TrialsAlzheimers Disease TrialsEssential Tremor TrialsAtopic Dermatitis TrialsOsteogenesis Imperfecta TrialsFanconi Anemia TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Columbus?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Columbus, OH